Nevro Corp. (NVRO) Stock Analysis

Nevro Corp. (NVRO) Healthcare & Pipeline Overview

Nevro Corp. specializes in neuromodulation technology for chronic pain, primarily through its Senza spinal cord stimulation system. With a focus on 10 kHz Therapy, the company addresses a significant market need, distributing its products via direct sales and partnerships in the United States and internationally.

What Is the Investment Thesis for NVRO?

The company's 10 kHz Therapy offers a differentiated approach to pain management, supported by clinical evidence. However, with a market cap of $224M and a negative profit margin of -27.8%, investors should carefully consider the financial risks. Key growth catalysts include expanding market penetration in the United States and internationally, as well as continued innovation in neuromodulation technology. The company's gross margin of 66.0% indicates strong pricing power, but profitability needs improvement. Monitoring the company's ability to manage costs and achieve profitability is crucial for assessing its long-term value.

Based on FMP financials and quantitative analysis

NVRO Key Highlights

Market Cap of $224M reflects the company's current valuation in the market.

• Gross Margin of 66.0% demonstrates strong pricing power and efficient production.
• Profit Margin of -27.8% indicates ongoing challenges in achieving profitability.
• Beta of 0.82 suggests lower volatility compared to the overall market.
• Nevro's focus on 10 kHz Therapy provides a differentiated approach to chronic pain management.

Who Are NVRO's Competitors?

NVRO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are NVRO's Key Strengths?

Innovative 10 kHz Therapy.

• Strong clinical evidence.
• Established distribution network.
• Advanced Senza Omnia system.

What Are NVRO's Weaknesses?

Negative profit margin.

• Limited product diversification.
• High reliance on spinal cord stimulation.
• Smaller market share compared to larger competitors.

What Could Drive NVRO Stock Higher?

Publication of new clinical data supporting the efficacy of 10 kHz Therapy.

• Expansion of the sales force to increase market penetration in key regions.
• Development and launch of next-generation neuromodulation systems.
• Regulatory approvals for new indications and product enhancements.

What Are the Key Risks for NVRO?

Financial-distress signal — its Altman Z-Score of -0.60 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-43.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from established medical device companies with greater resources.
• Regulatory changes and reimbursement pressures affecting pricing and market access.
• Economic downturns leading to reduced healthcare spending.
• Product liability claims and recalls impacting brand reputation.

What Are the Growth Opportunities for NVRO?

• Expansion in International Markets: Nevro has the opportunity to expand its presence in international markets, particularly in Europe and Asia-Pacific. These regions have a growing aging population and increasing awareness of chronic pain management solutions. By establishing strategic partnerships and expanding its distribution network, Nevro can tap into these markets and drive revenue growth. The global market for spinal cord stimulation devices is expected to grow, offering a substantial opportunity for Nevro to increase its international sales.
• Product Innovation and Development: Continued investment in research and development is crucial for Nevro to maintain its competitive edge. Developing new and improved neuromodulation technologies, such as advanced spinal cord stimulation systems and therapies for other chronic pain conditions, can attract new customers and increase market share. Innovation in areas like closed-loop stimulation and personalized therapy could further differentiate Nevro's offerings and drive adoption.
• Strategic Partnerships and Acquisitions: Nevro can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with other medical device companies or acquiring complementary technologies can enhance Nevro's offerings and provide access to new markets. For example, partnering with a company specializing in pain diagnostics could improve patient selection and treatment outcomes, driving adoption of Nevro's Senza system.
• Increased Awareness and Adoption of 10 kHz Therapy: Nevro can focus on increasing awareness and adoption of its 10 kHz Therapy among physicians and patients. By conducting clinical trials, publishing research papers, and educating healthcare providers about the benefits of 10 kHz Therapy, Nevro can drive adoption of its Senza system. Increased awareness can lead to greater patient demand and higher sales volumes, contributing to revenue growth.
• Expansion into New Pain Management Areas: Nevro can explore opportunities to expand its neuromodulation technology into new pain management areas beyond spinal cord stimulation. This could include developing therapies for peripheral nerve stimulation, sacral nerve stimulation, or other chronic pain conditions. By diversifying its product portfolio, Nevro can reduce its reliance on spinal cord stimulation and tap into new markets, driving long-term growth.

What Are NVRO's Competitive Advantages?

• Proprietary 10 kHz Therapy technology.
• Strong clinical evidence supporting the efficacy of Senza system.
• Established distribution network in the United States and internationally.
• Brand recognition and reputation in the neuromodulation market.

What Does NVRO Do?

Nevro Corp., founded in 2006 and headquartered in Redwood City, California, is a medical device company focused on providing innovative solutions for chronic pain management. The company's core product is the Senza spinal cord stimulation (SCS) system, a neuromodulation platform designed to alleviate chronic pain through its unique 10 kHz Therapy. This therapy delivers electrical pulses to the spinal cord, modulating nerve activity and reducing pain signals. The Senza system includes the Senza II and Senza Omnia systems, offering advanced features and customization options to meet individual patient needs. Nevro distributes its products through a direct sales force in the United States and through a network of sales agents and independent distributors internationally, ensuring broad market access. The company's commitment to evidence-based medicine is reflected in its rigorous clinical trials and data-driven approach to product development, positioning it as a key player in the neuromodulation space. Nevro continues to innovate and expand its product offerings to address the diverse needs of patients suffering from chronic pain, solidifying its presence in the global medical device market.

What Products and Services Does NVRO Offer?

• Develops and commercializes the Senza spinal cord stimulation (SCS) system.
• Offers 10 kHz Therapy for chronic pain management.
• Provides the Senza II and Senza Omnia systems for advanced neuromodulation.
• Distributes products through a direct sales force in the United States.
• Utilizes a network of sales agents and independent distributors internationally.
• Focuses on evidence-based neuromodulation solutions.
• Addresses chronic pain conditions through innovative medical devices.

How Does NVRO Make Money?

• Develops and manufactures spinal cord stimulation systems.
• Sells SCS systems and related accessories to hospitals and clinics.
• Provides training and support to healthcare professionals.
• Generates revenue through direct sales and distribution partnerships.

What Industry Does NVRO Operate In?

The medical device industry, particularly the neuromodulation segment, is experiencing growth driven by an aging population and increasing prevalence of chronic pain. The market is competitive, with major players like Medtronic and Boston Scientific also offering spinal cord stimulation devices. Nevro's focus on 10 kHz Therapy differentiates it from competitors, offering a unique approach to pain management. The industry is subject to regulatory scrutiny and requires significant investment in research and development.

Who Are NVRO's Key Customers?

• Hospitals and clinics specializing in pain management.
• Physicians who treat patients with chronic pain.
• Patients suffering from chronic pain conditions.
• Healthcare providers seeking neuromodulation solutions.

Nevro Corp. (NVRO) Valuation Context

Valued at $224M, NVRO is classified as a micro-cap stock.

NVRO Revenue & Earnings Trend

In Dec 2024, NVRO generated $105.5M in top-line revenue, marking a sequential increase of 8.9%. The company recorded a net loss of $53.1M, with diluted EPS of $-1.41. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, NVRO averaged $-0.76 in diluted EPS.

Company Profile

Nevro Corp. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Kevin R. Thornal. NVRO has traded publicly since 2014.

Return on equity for Nevro Corp. stands at -43.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -13.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.62 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -52.4%, the inverse of the P/E and a quick read on earnings relative to price.

Nevro Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.60 places it in the distress zone, a signal of elevated financial risk.

Nevro Corp. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 24.5% above estimates on average.

Wall Street analysts project Nevro Corp. revenue of about $423.7M for fiscal 2026, with EPS near $-2.09. The estimate reflects 8 contributing analysts.

The most recent 12 insider filings for Nevro Corp. break down as 12 sales and 0 purchases. On net that is roughly 2.0M shares disposed (about $11.5M), a signal worth weighing alongside the fundamentals.

NVRO Financials

NVRO Latest News

Nevro Corp. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources